Research ExplorerPublicationsOncological impact of cystoscopic findings in non-muscle-inv...

Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer

Standard

Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer. / Yanagisawa, Takafumi; Quhal, Fahad; Kawada, Tatsushi; Mostafaei, Hadi; Sari Motlagh, Reza; Laukhtina, Ekaterina; Rajwa, Pawel; von Deimling, Markus; Bianchi, Alberto; Pallauf, Maximilian; Majdoub, Muhammad; Pradère, Benjamin; Abufaraj, Mohammad; Moschini, Marco; Karakiewicz, Pierre I; Iwatani, Kosuke; Miki, Jun; Kimura, Takahiro; Shariat, Shahrokh F.

In: BJU INT, Vol. 131, No. 6, 06.2023, p. 643-659.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Yanagisawa, T, Quhal, F, Kawada, T, Mostafaei, H, Sari Motlagh, R, Laukhtina, E, Rajwa, P, von Deimling, M, Bianchi, A, Pallauf, M, Majdoub, M, Pradère, B, Abufaraj, M, Moschini, M, Karakiewicz, PI, Iwatani, K, Miki, J, Kimura, T & Shariat, SF 2023, 'Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer', BJU INT, vol. 131, no. 6, pp. 643-659. https://doi.org/10.1111/bju.15944

APA

Yanagisawa, T., Quhal, F., Kawada, T., Mostafaei, H., Sari Motlagh, R., Laukhtina, E., Rajwa, P., von Deimling, M., Bianchi, A., Pallauf, M., Majdoub, M., Pradère, B., Abufaraj, M., Moschini, M., Karakiewicz, P. I., Iwatani, K., Miki, J., Kimura, T., & Shariat, S. F. (2023). Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer. BJU INT, 131(6), 643-659. https://doi.org/10.1111/bju.15944

Vancouver

Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Sari Motlagh R, Laukhtina E et al. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer. BJU INT. 2023 Jun;131(6):643-659. https://doi.org/10.1111/bju.15944

Bibtex

@article{efdb836f79e84f15b200af812fce3e94,
title = "Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer",
abstract = "ObjectiveTo assess the association between cystoscopic findings and oncological outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified.MethodsMultiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence-free (RFS), progression-free (PFS), and cancer-specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC.ResultsOverall, 73 studies comprising 28 139 patients were eligible for the meta-analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48–1.74) and PFS (pooled HR 1.44, 95% CI 1.18–1.76) in NMIBC patients (including both Ta and T1). Tumour size (≥3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69–2.30) and PFS (pooled HR 1.81, 95% CI 1.52–2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (≥3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette-Gu{\'e}rin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (≥3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52–3.01) and PFS (pooled HR 2.17, 95% CI 1.42–3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25–2.72) and PFS (pooled HR 3.06, 95% CI 2.31–4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63–3.30).ConclusionsCystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision-making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy.",
author = "Takafumi Yanagisawa and Fahad Quhal and Tatsushi Kawada and Hadi Mostafaei and {Sari Motlagh}, Reza and Ekaterina Laukhtina and Pawel Rajwa and {von Deimling}, Markus and Alberto Bianchi and Maximilian Pallauf and Muhammad Majdoub and Benjamin Prad{\`e}re and Mohammad Abufaraj and Marco Moschini and Karakiewicz, {Pierre I} and Kosuke Iwatani and Jun Miki and Takahiro Kimura and Shariat, {Shahrokh F}",
year = "2023",
month = jun,
doi = "10.1111/bju.15944",
language = "English",
volume = "131",
pages = "643--659",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer

AU - Yanagisawa, Takafumi

AU - Quhal, Fahad

AU - Kawada, Tatsushi

AU - Mostafaei, Hadi

AU - Sari Motlagh, Reza

AU - Laukhtina, Ekaterina

AU - Rajwa, Pawel

AU - von Deimling, Markus

AU - Bianchi, Alberto

AU - Pallauf, Maximilian

AU - Majdoub, Muhammad

AU - Pradère, Benjamin

AU - Abufaraj, Mohammad

AU - Moschini, Marco

AU - Karakiewicz, Pierre I

AU - Iwatani, Kosuke

AU - Miki, Jun

AU - Kimura, Takahiro

AU - Shariat, Shahrokh F

PY - 2023/6

Y1 - 2023/6

N2 - ObjectiveTo assess the association between cystoscopic findings and oncological outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified.MethodsMultiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence-free (RFS), progression-free (PFS), and cancer-specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC.ResultsOverall, 73 studies comprising 28 139 patients were eligible for the meta-analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48–1.74) and PFS (pooled HR 1.44, 95% CI 1.18–1.76) in NMIBC patients (including both Ta and T1). Tumour size (≥3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69–2.30) and PFS (pooled HR 1.81, 95% CI 1.52–2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (≥3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette-Guérin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (≥3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52–3.01) and PFS (pooled HR 2.17, 95% CI 1.42–3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25–2.72) and PFS (pooled HR 3.06, 95% CI 2.31–4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63–3.30).ConclusionsCystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision-making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy.

AB - ObjectiveTo assess the association between cystoscopic findings and oncological outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified.MethodsMultiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence-free (RFS), progression-free (PFS), and cancer-specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC.ResultsOverall, 73 studies comprising 28 139 patients were eligible for the meta-analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48–1.74) and PFS (pooled HR 1.44, 95% CI 1.18–1.76) in NMIBC patients (including both Ta and T1). Tumour size (≥3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69–2.30) and PFS (pooled HR 1.81, 95% CI 1.52–2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (≥3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette-Guérin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (≥3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52–3.01) and PFS (pooled HR 2.17, 95% CI 1.42–3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25–2.72) and PFS (pooled HR 3.06, 95% CI 2.31–4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63–3.30).ConclusionsCystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision-making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy.

U2 - 10.1111/bju.15944

DO - 10.1111/bju.15944

M3 - SCORING: Review article

C2 - 36479820

VL - 131

SP - 643

EP - 659

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 6

ER -